PCNSL Clinical Trial
Official title:
Plasma and Cerebrospinal Fluid (CSF) Pharmacokinetics of Bendamustine as a Component of Salvage Therapy for Primary Central Nervous System Lymphoma (PCNSL)
This pilot study will i) evaluate the efficacy and the safety of bendamustine-based combination chemotherapy and ii) investigate the pharmacokinetics (PK)of bendamustine in plasma and CSF when given as salvage treatment for patients with relapsed or refractory primary central nervous system lymphoma (PCNSL).
A relatively high proportion of patients diagnosed with primary CNS lymphoma will experience recurrent disease, yet therapy options are limited in salvage therapy. Based on the demonstrated activity and proposed additive mechanisms of the chemotherapeutic agents included in the bendamustine-based combination regimen, the efficacy and safety of R-B(O)AD will be evaluated for treatment of relapsed/refractory (R/R) primary CNS lymphoma. Evidence from previous preclinical tissue distribution studies and single agent intravenous drug therapy trials in CNS malignancies suggests that bendamustine penetrates brain and tumor tissue, however there are no clinical data available on the PK of bendamustine in the CSF. This study will evaluate the PK of plasma and CSF drug levels through a population based nonlinear mixed-effects model approach in a R/R PCNSL cohort with the goals to define the currently unknown PK profile of bendamustine in the CSF and to further characterize the relationship between plasma and CSF drug levels, and the influence of exposure on response to therapy. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05167630 -
Prognosis Factors in Patients With Primary Central Nervous System Lymphoma
|
||
Recruiting |
NCT04514393 -
Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma
|
Phase 2 | |
Recruiting |
NCT04481815 -
Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT04438044 -
A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL
|
Phase 2 | |
Recruiting |
NCT05896007 -
Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT
|
Phase 2 | |
Not yet recruiting |
NCT05021770 -
Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05782374 -
Real World Data on Ibrutinib Use in PCNSL Rel/Ref
|